letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...5960616263646566676869...100101»
  • ||||||||||  letrozole / Generic mfg., tamoxifen / Generic mfg.
    Review, Journal:  Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer. (Pubmed Central) -  Jun 27, 2020   
    The majority (>80%) of high grade serous, low grade serous and endometrioid carcinomas and many granulosa cell tumors express ER-alpha (ERα), and these tumor types have demonstrated responses to endocrine therapy (tamoxifen and aromatase inhibitors) in multiple clinical studies...The more recently identified G protein-coupled receptor (GPER1; GPR30) has been shown to mediate both tumor-suppressive and tumor-promoting action in ovarian cancer cells, suggesting a more complex role. This review will summarize recent findings in this field.
  • ||||||||||  Lynparza (olaparib) / Merck (MSD), AstraZeneca
    Trial completion date, Trial primary completion date, PARP Biomarker:  IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC (clinicaltrials.gov) -  Jun 25, 2020   
    P1,  N=143, Recruiting, 
    Our data support treatment guideline recommendations involving the new combinations of hormone therapies plus targeted therapies as first-line or second-line treatments, or in both settings, in women with hormone-receptor-positive, HER2-negative metastatic breast cancer. Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Jun 2021
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  Berberine decreases insulin resistance in a PCOS rats by improving GLUT4: Dual regulation of the PI3K/AKT and MAPK pathways. (Pubmed Central) -  Jun 25, 2020   
    In the present study, female Sprague-Dawley (SD) rats were given oral letrozole to establish a model of insulin-resistant PCOS, and animals were then randomized into untreated or berberine-treated groups (400, 200, or 100 mg/kg)...We further found that 400 mg/kg berberine treatment was associated with activation of PI3K/AKT signaling and suppression of the MAPK pathway. In conclusion, berberine has the potential to reduce PCOS pathology and IR values in a rat model system through a mechanism linked to GLUT4 upregulation via PI3K/AKT activation and MAPK pathway suppression.
  • ||||||||||  fluorouracil / Generic mfg., Herceptin (trastuzumab) / Roche, cyclophosphamide intravenous / Generic mfg.
    Journal:  Drug utilization and expenditure of anticancer drugs for breast cancer. (Pubmed Central) -  Jun 23, 2020   
    The most commonly prescribed medication was fluorouracil, epirubicin, and cyclophosphamide (FEC) regimen, which was used in 81% of patients...Docetaxel was the most commonly used drug in neoadjuvant setting, whereas letrozole and trastuzumab were prescribed more frequently in hormonal and targeted therapies, respectively...Our results indicated that adherence to a clinical guideline and recommended medication regimens improved patient outcomes. Our finding indicate how analyzing drug utilization pattern could benefit institutions in managing inventory and efficiently using health care resources.
  • ||||||||||  letrozole / Generic mfg., Faslodex (fulvestrant) / AstraZeneca
    [VIRTUAL] A Prospective Non-surgical Treatment for Inguinal Hernias () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1931;    
    Ablation of estrogen production or its signaling not only completely prevents this phenotype but also reverses mild to moderate-sized hernias. Our findings pave the pathway for developing the first potential preventive and therapeutic pharmacological approach for combating recurrent inguinal hernias in elderly men through modulation of estrogen signaling in abdominal muscle tissue.
  • ||||||||||  [VIRTUAL] Anthropometric and Reproductive Outcomes of Patients with Gonadotropin-Independent Precocious Puberty Due to McCune-Albright Syndrome After Treatment with Distinct Therapeutic Agents () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1604;    
    All patients were treated with one or more of the following agents: tamoxifen, medroxyprogesterone acetate, aromatase inhibitors (anastrozole or letrozole) and anti-androgens (cyproterone), and, in cases with secondary gonadotropic axis activation, depot GnRHa was used...Tamoxifen plus medroxyprogesterone, or cyproterone, or leuprorelin were used (each one) as the first choice in 1 patient (7.6%)...Despite a reasonable number of treatment options for peripheral PP in MAS, none of them showed proven effective results in stopping vaginal bleeding, reduce pubertal progression and preserving potential genetic adult height. Therefore, due to the extremely heterogeneous nature of PPP of MAS, the clinical treatment remains a challenge.
  • ||||||||||  letrozole / Generic mfg.
    [VIRTUAL] Increased In Vivo Pulsatile LH Secretion and Hypothalamic Kisspeptin, NKB, and Dynorphin RNA Levels in a PCOS-Like Mouse Model () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1363;    
    Females given constant, long-term letrozole to reduce aromatase activity demonstrate PCOS-like phenotypes, including polycystic ovaries, anovulation, elevated circulating testosterone, and increased LH...Our findings demonstrate that LET mice, like PCOS women, have markedly elevated LH pulsatility which likely drives increased ovarian androgen secretion. Increased arcuate kisspeptin and NKB levels may be fundamental contributors to the enhanced stimulation of LH pulse secretion in this PCOS-like condition, and perhaps, in some PCOS women.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Trial completion date, Trial primary completion date:  Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS) (clinicaltrials.gov) -  Jun 17, 2020   
    P2,  N=195, Recruiting, 
    ΔKi67 score evaluated between basal and residual tumor at definitive surgery showed to be highly predictive of clinical complete response, and a potential parameter to be used for predicting disease-free survival and overall survival in luminal breast cancer treated with neoadjuvant endocrine-based therapy. Trial completion date: Nov 2019 --> Nov 2020 | Trial primary completion date: Nov 2019 --> Nov 2020
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Ibrance (palbociclib) / Pfizer
    Enrollment open, Metastases:  PALVEN: Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer (clinicaltrials.gov) -  Jun 11, 2020   
    P1b,  N=36, Recruiting, 
    Trial completion date: Jun 2020 --> Jun 2022 | Trial primary completion date: Jun 2020 --> Jun 2022 Not yet recruiting --> Recruiting
  • ||||||||||  letrozole / Generic mfg., zoledronic acid / Generic mfg.
    Clinical, P3 data, Journal:  Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial. (Pubmed Central) -  Jun 10, 2020   
    P3
    The combination of depo-leuprolide acetate monthly for 60 days combined with daily letrozole has better clinical outcomes at IVF in women with endometriomas than depo-leuprolide acetate treatment alone. HOBOE study shows that in premenopausal patients with early breast cancer undergoing ovarian function suppression with triptorelin, ZL significantly improves DFS, while worsening compliance and toxicity, as compared with T. (NCT00412022).
  • ||||||||||  letrozole / Generic mfg., everolimus / Generic mfg.
    Trial completion date, Trial primary completion date, Metastases:  Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer (clinicaltrials.gov) -  Jun 9, 2020   
    P2,  N=42, Active, not recruiting, 
    HOBOE study shows that in premenopausal patients with early breast cancer undergoing ovarian function suppression with triptorelin, ZL significantly improves DFS, while worsening compliance and toxicity, as compared with T. (NCT00412022). Trial completion date: Apr 2021 --> Apr 2022 | Trial primary completion date: Apr 2020 --> Apr 2021
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Trial completion date, Trial primary completion date:  Palbociclib and FES PET (clinicaltrials.gov) -  Jun 9, 2020   
    P2,  N=30, Active, not recruiting, 
    Trial completion date: Apr 2021 --> Apr 2022 | Trial primary completion date: Apr 2020 --> Apr 2021 Trial completion date: May 2020 --> May 2022 | Trial primary completion date: May 2020 --> May 2022
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Enrollment open, Metastases:  CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer (clinicaltrials.gov) -  Jun 8, 2020   
    P2,  N=204, Recruiting, 
    Trial completion date: May 2020 --> May 2022 | Trial primary completion date: May 2020 --> May 2022 Active, not recruiting --> Recruiting
  • ||||||||||  letrozole / Generic mfg.
    Review, Journal:  Recent advances in the understanding and management of polycystic ovary syndrome. (Pubmed Central) -  Jun 8, 2020   
    Of note, the aromatase inhibitor letrozole seems to be more effective than the reference drug clomiphene citrate to treat infertility due to PCOS. Integral management by a multidisciplinary team may help the patients to adhere to lifestyle interventions and thereby reduce body adiposity and recover their metabolic and reproductive health.
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  Effect of adding letrozole to gonadotropin on in vitro fertilization outcomes: An RCT. (Pubmed Central) -  Jun 6, 2020   
    There were no significant differences in fertilization rate and chemical and clinical pregnancy rates between the two groups. Although adding letrozole to gonadotropin in normal responders reduces the total dose of gonadotropin, it does not improve the pregnancy outcomes.
  • ||||||||||  letrozole / Generic mfg.
    Enrollment open:  Protocols of IVF/ICSI in Poor Responders (clinicaltrials.gov) -  Jun 3, 2020   
    P3,  N=134, Recruiting, 
    Trial completion date: Dec 2019 --> Dec 2021 Not yet recruiting --> Recruiting
  • ||||||||||  Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
    Trial completion date, Trial primary completion date, Metastases:  CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) -  May 31, 2020   
    P1,  N=256, Active, not recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021